ARCUS®: A Commercialized Technology Enabling High-Dose, Highly Respirable Powders
Summary:Spray drying to manufacture powders for inhalation is now a well-established practice in the pharmaceutical industry that allows for the production of highly respirable, high-dose formulations. ARCUS technology incorporates the benefits of spray drying with a capsule-based high-capacity device. As one of only three commercially approved technologies for spray drying inhalable powder, ARCUS provides an opportunity to design an inhalation product with an established and successful regulatory track record. In this article, Dr. Alan Watts, Director of Innovation & Partnerships for Orally Inhaled Products at Catalent, and Michael Tauber, Senior Director of Pharmaceutical Development at Acorda Therapeutics discuss the requirements and benefits of using spray-dried powders for inhalation, and how ARCUS can be used to successfully bring new inhaled therapies to market.